Shots:
Contineum Therapeutics reported the initiation of patient dosing in exploratory P-Ib study of PIPE-791 for chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP)
The company expects to enroll approx. 40 pts. for a treatment duration of 28 days and anticipates topline data in early 2026
PIPE-791…
